腾讯网29 天
全球第 2 款！FDA 批准创新 CSF1R 抑制剂上市
当地时间 2 月 14 日，美国 FDA 宣布已批准 Ono Pharmaceutical 的 CSF1R 抑制剂 Vimseltinib 上市，用于治疗不适合手术切除的腱鞘巨细胞瘤（TGCT）患者。
靶向药物：培西达替尼（Turalio Pexidartinib）
培西达替尼（Pexidartinib，商品名：Turalio）是一种激酶抑制剂，主要用于治疗无法通过手术改善且伴有严重发病率或功能受限的症状性腱鞘巨细胞瘤（TGCT）成人患者。
Nature7 天
FDA approves CSF1R inhibitor for rare, non-cancerous joint tumours
The FDA has approved Ono’s CSF1R inhibitor vimseltinib (Romvimza) for adults with symptomatic tenosynovial giant cell tumours (TGCT) that are not suitable for surgical resection. It will compete ...
Researchers identify genetic mutations for rare disorder causing cognitive decline
More information: Jaroslaw Dulski et al, Global Presence and Penetrance of CSF1R -Related Disorder, Neurology Genetics (2024) ...
FiercePharma1 个月
FDA approves Ono's rare tumor drug from $2.4B Deciphera buyout
Like Turalio, which in 2019 became the first FDA-approved therapy to treat TGCT, Romvimza is also an inhibitor of the colony-stimulating factor 1 receptor (CSF1R). Romvimza only recently came into ...
Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging ...
Among the 7MM, the United States had the highest prevalence of tenosynovial giant cell tumor, accounting for approximately 45 ...